AstraZeneca Gets A Reprieve But Will Have To Earn Its Independence
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer has walked away from AstraZeneca – for now – but the big pharma can make another offer later this year under U.K. takeover laws. AstraZeneca will need to give investors a reason to believe it deserves to go it alone.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.